FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: ~~09/154,334~~ 10/033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: ~~1614~~ 1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5 8 5 9 2 5 7	01/12/9	Talley	548	247	08/14/96
	AB	5 8 6 3 9 2 2	01/26/99	Mayer, et al.	514	270	07/02/99
	AC	5 8 4 0 7 3 1	11/24/98	Mayer, et al.	514	289	08/02/95
	AD	5 8 6 9 4 9 8	02/09/99	Mayer, et al.	514	282	07/07/97
	AE	5 8 6 1 4 1 9	01/19/99	Dube, et al.	514	334	07/11/97
	AF	5 7 8 9 4 1 3	08/04/98	Black, et al.	514	255	01/21/97
	AG	5 6 0 4 2 6 0	02./18/97	Guay, et al.	514	605	11/04/93
	AH	5 4 5 8 8 7 9	10/17/95	Singh, et al.	424	400	09/30/94
	AI	5 5 1 6 8 0 3	05/14/96	Raffa	514	570	03/01/95
	AJ	5 8 4 3 4 6 8	12/01/98	Burkoth, et al.	424	448	05/13/96
	AK						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX) By NSAIDS: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Palret, et al., Inflammopharmacology 4; 61-70, (1996).
	AM	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. Europeam J. Pharm 355 pp 211-217, (1998).
	AN	Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998).
	AO	Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996).
	AP	Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. And Applied Skin Phys. 11: 273-278, (1998).
	AQ	Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cartiona Hay and Jacqueline de Belleroche, NeuroReport 8, 1249-1251, (1997).
	AR	The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996).
	AS	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47: 79-85, (1998).
	AT	Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, Vol. 16, No. 2, pp. 181-206, (1996).

EXAMINER	DATE CONSIDERED
	6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 09/154,394 10/033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: ~~1614~~ 1639

1879 U.S. PTO 10/033055

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES
	BL						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BM	Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. Vol. 12 pp. 1063-1073 (1998).
	BN	Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With An Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996).
	BO	Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).
	BP	Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15 , (1996).
	BR	Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Viscemonociception Induced by Phenylquinone, Hidenobu Kusuhara, et al. Prostaglandins 55: 43-49, (1998).
	BS	Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. D. Dirig, et al. J. Pharmacol. And Experimental Therapeutics Vol285, No. 3, pp 1031-1038.
	BT	

EXAMINER	DATE CONSIDERED 6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 09/154,354 10/033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, *et. al.*	
		FILING DATE: September 17, 1998	GROUP: ~~1627~~ 1639

JC879 U.S. PTO 10/033055 12/27/01

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AE	9907413	2/18/99	WO				
	AF	9932119	7/1/99	WO				
	AG							
	AH							
	AI							
	AJ							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. *British Journal of Anaesthesia* 84 (2) 151-4 (2000).
	AL	Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats, C.S. Wong et al., *British Journal of Anaesthesia* 85 (5) 747-51 (2000).
	AM	Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons, M. Melis, et al. *Eur. J. Pharmacology* 387 (1) R1-R3 (2000).
	AN	Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats, J.M. Lashbrook, et al. *Pain* 82 (1) 65-72 (1999).
	AO	Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones, Vaughn et al. *British Journal of Pharmacology* 123 (8) 1479-81 (1998).
	AP	
	AQ	

EXAMINER	DATE CONSIDERED
	6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 09/154,354 10/033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: ~~1618~~ 1639

JC879 U.S. PTO 10/033055 12/27/01

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5 4 7 4 9 9 5	12/12/95	Ducharme et al.	514	241	01/10/94
	AB	5 6 9 1 3 7 4	11/25/97	Black et al.	514	473	05/18/95

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
	6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 09/154,834 10/033,055 PTO
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: 1614 1637

JC979 U.S. PTO 10/033055 12/27/01

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3 8 0 0 0 4 1	03/26/74	Miller, et al.	424	273	03/02/71
	AB	4 3 2 2 4 2 7	03/30/82	Buyinski, et al.	424	260	04/16/81
	AC	4 3 3 8 3 2 4	06/06/82	Gardocki	424	266	03/17/81
	AD	4 4 0 4 2 1 0	09/13/83	Schmidt	424	260	06/30/82
	AE	4 4 0 7 8 0 4	10/04/83	Schmidt	424	260	06/30/82
	AF	4 4 0 7 8 0 5	10/04/83	Schmidt	424	260	06/30/82
	AG	4 4 6 4 3 7 6	08/07/84	Sunshine, et al.	424	253	10/11/83
	AH	4 4 8 6 4 3 6	12/04/84	Sunshine, et al.	424	253	03/11/83
	AI	4 4 8 9 0 8 0	12/18/84	Lomen	424	260	12/06/82

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AJ	2 0 2 3 3 4 9	02/18/91	Canada	A61K	31/44		
	AK	0 2 7 4 8 4 5	07/20/88	EP (A1)	A61K	31/19		
	AL	0 3 8 8 1 2 5	09/19/90	EP (A1)	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. Arzneim.-Forsch./Drug Res. 46 (I), 57-63 (1996).
	AN	Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G. K. Vlok, et al. Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg. pp 3-6, (1987).
	AO	
	AP	
	AQ	

EXAMINER	DATE CONSIDERED
	6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: ~~09/134,334~~ 10/033,057
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: ~~1614~~ 1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	4	5	6	7	1	8	3	01/28/86	Sunshine, et al.	514	264	12/12/83
	BB	4	5	6	9	9	3	7	02/11/86	Baker, et al.	514	282	02/11/83
	BC	4	5	7	1	4	0	0	02/18/86	Arnold	514	282	12/18/84
	BD	4	5	8	7	2	5	2	05/06/86	Arnold	514	282	12/18/84
	BE	4	6	1	9	9	3	4	12/28/86	Sunshine, et al.	514	277	07/08/85
	BF	4	6	9	0	9	2	7	09/01/87	Voss, et al.	514	282	02/03/86
	BG	4	8	3	9	1	7	6	06/13/89	Pahkhania, et al.	424	465	12/08/87
	BH	4	8	4	4	9	0	7	07/04/89	Elger, et al.	424	465	08/14//86
	BI	4	9	2	7	8	5	4	05/22/90	Sunshine, et al.	514	570	08/21/89
	BJ	5	1	6	4	3	9	8	12/17/92	Sims, et al.	514	282	04/01/91
	BK	5	1	9	0	9	4	7	03/02/93	Riess, et al.	514	282	08/16/91
	BL	5	2	4	0	6	9	4	08/31/93	Gwaltney, Jr.	424	45	12/19/91

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	BM	0	0	6	8	8	3	8	06/25/82	EP (A1)	A61K	31/485		
	BN	0	0	6	8	8	3	8	06/25/82	EP (B1)	A61K	31/485		
	BO	2	0	8	1	6	0	4	05/01/95	Canada	A61K	031/135		
	BP													
	BQ													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER	DATE CONSIDERED
	6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: ~~09/134,334~~ 10/033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: ~~1614~~ 1639

1c879 U.S. PTO 10/033055 12/27/01

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5 4 0 9 9 4 4	04/25/95	Black, et al.	514	359	03/12/93
	AB	5 4 3 6 2 6 5	06/25/95	Black, et al.	514	420	11/12/93
	AC	5 5 1 0 3 6 8	04/23/96	Lau, et al.	514	419	05/22/95
	AD	5 5 2 1 2 1 3	05/28/96	Prasit, et al.	514	443	08/29/94
	AE	5 5 5 0 1 4 2	08/27/96	Ducharme et al.	514	365	05/08/95
	AF	5 5 5 2 4 2 2	09/03/96	Gauthier, et al.	514	368	01/11/95
	AG	5 6 0 4 2 5 3	02/18/97	Lau, et al.	514	415	05/22/95
	AH	5 6 3 9 7 8 0	06/17/97	Lau, et al.	514	419	05/22/95
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AJ							
	AK							
	AL							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, *Supplement 2* (1998).
	AN	
	AO	
	AP	
	AQ	

EXAMINER	DATE CONSIDERED
	6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: ~~09/154,334~~ 10/033,050
	LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: ~~1627~~ 1639

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AA	0 6 5 4 2 6 3	05/24/95	EP (A1)	A61K	31/135		
	AB	0 6 5 4 2 6 3	05/24/95	EP (B1)	A61K	31/135		
	AC	9 7 1 7 9 7 8	05/22/97	WO	A61K	33/00		
	AD	9 7 2 5 9 8 8	07/24/97	WO	A61K	31/495		
	AE	9 7 3 2 8 5 7	09/12/97	WO	C07D	241/104		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Dray et al. New Pharmacological Strategies for Pain Relief. Annual Review of Pharmacology &Toxicology, 36, pp. 253-280. (1996).
AG	Brasseur. L. Revue des therapeutiques pharmacolgoiques actuelles de la douleur. Drugs,53 Suppl 2, pp. 10-17. (1997)
AH	Rang et al. New molecules in analgesia. British Journal of Anesthesia, 75, pp. 145-156 (1995)
AI	Beaver, WT. Combination Analgesics. American Journal of Medicine, 77 (Suppl 3A), pp. 38-53. (1984).
AJ	Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In Evaluation and Treatment of Chronic Pain, 2nd ed., William & Wilkins pp. 363-383. (1992).
AK	Goodman & Gilman's. The Pharmacological Basis of Therapeutics, 9th Edition. McGraw-Hill, New York, pp 535 and 551-552.
AL	Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. Pain, 73, 3 pp. 401-406. (1997).
AM	Etches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. Anesthesia & Analgesia, 81 (6), pp. 1175-1180. (1995).
AN	Hodsman et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. Anaesthesia, 42(9), pp. 1005-1008. (1987).
AO	Kaasalainer et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. Pain, 70, 2-3, pp. 175-183. (1997).
AP	Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. Journal of Clinical Pharmacology, 37 (10), pp. 908-915. (1997).
AQ	Insel. Chapter 27: Analgesic-Antipyretic and Anti-Inflammatory Agents. In Hardman, ed., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition. McGraw-Hill, New York, pp. 654-655. (1996).
AR	Polisson. Non-steroidal Anti-inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. The American Journal of Medicine, 100 (Suppl 2A), pp. 2A-31S - 2A-36S. (1996).
AS	Vane, J. Towards a better aspirin. Nature, 367, pp. 215-216. (1994).
AT	Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. Journal of Clinical Rheumatology, 2 (3), pp. 135-140. (1996).

EXAMINER	DATE CONSIDERED 6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: ~~09/154,354~~ 10/033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: ~~1827~~ 1639

		OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	BA	Van Ryn et al. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. Expert Opinion On Investigational Drugs. pp. 609-614. (1997).
	BB	Vane et al. New insights into the mode of action of anti-inflammatory drugs. Inflammation Research. 44, (No.1), pp 1-10 (1995).
	BC	Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. British Journal of Rheumatology. 34, Abstract Suppl. 1, p. 48. (1995). Abstract.
	BD	Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. Journal of Rheumatology. Vol. 24, Suppl 49, pp. 20-24. (1997).
	BE	Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. Neuropharmacology Vol. 33, pp. 1609-1611. (1994).
	BF	Donelly et al. COX-II Inhibitors - a new generation of safer NSAIDS? Alimentary Pharmacology and Therapeutics, 11, 2, pp. 227-236. (1997).
	BG	Wallace, J.L. Nonsteroidal Anti-Inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. Gastroenterology, 112, 3, pp. 1000-1016. (1997).
	BH	Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. J Rheumatoloty, 24, Suppl. 47, pp. 32-39. (1997).
	BI	Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Muscoskeletal Disease: A Canadian Consensus. Canadian Medical Association Journal, 155, 1, pp. 77-88. (1996).
	BJ	Mehlisch et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. Journal of Clinical Pharmacology, 37, 9, 863. (1997). Abstract.
	BK	Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointesinal Toxicity. Gut, 39, Suppl. 3, A151. (1996). Abstract.
	BL	Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). Journal Of Medicinal Chemistry, 40(9), 1347-65. (1997).
	BM	Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. Journal Of Rheumatology, 24 Suppl 49, pp. 9-14. (1997).
	BN	
	BO	
	BP	
	BQ	
	BR	
	BS	
	BT	

EXAMINER	DATE CONSIDERED 6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079US

SERIAL NO.: ~~09/154,354~~ 10/033,055

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: September 17, 1998

GROUP: ~~1627~~ 1639

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
[illegible]	AH	0 7 3 4 2 7 5	11/04/1997	Australia	C07D	261/08		
	AI							
	AJ							
	AK							
	AL							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM
	AN
	AO
	AP
	AQ
	AR
	AS

EXAMINER [signature]

DATE CONSIDERED 6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.